Clinical trial
The Correlation Between Homologous Recombination Deficiency Detection and the Efficacy of PARP Inhibitors in Ovarian Cancer
NCT06242392 is registered in ClinicalTrials.gov with Fujian Cancer Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- The Correlation Between Homologous Recombination Deficiency Detection and the Efficacy of PARP Inhibitors in Ovarian Cancer
- Lead sponsor
- Fujian Cancer Hospital
- Phase
- Observational
- Overall status
- Unknown status
- Start date
- January 31, 2024
- Completion date
- July 1, 2026
- Enrollment
- 250 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.